For: | Dietrich CG, Rau M, Geier A. Screening for nonalcoholic fatty liver disease-when, who and how? World J Gastroenterol 2021; 27(35): 5803-5821 [PMID: 34629804 DOI: 10.3748/wjg.v27.i35.5803] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v27/i35/5803.htm |
Number | Citing Articles |
1 |
Mahdi Barazesh, Sajad Jalili, Morteza Akhzari, Fouzieyeh Faraji, Ebrahim Khorramdin. Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities,
and Management of Non-alcoholic Fatty Liver Disorder. Current Drug Therapy 2024; 19(1): 20 doi: 10.2174/1574885518666230417111247
|
2 |
Markos Kalligeros, Athanasios Vassilopoulos, Fadi Shehadeh, Stephanos Vassilopoulos, Ingrid Lazaridou, Eleftherios Mylonakis, Kittichai Promrat, Jack R. Wands. Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2023; 21(7): 1708 doi: 10.1016/j.cgh.2023.01.001
|
3 |
Chun-Yi Wang, Hsiang-Han Kao, Kuan-Yu Lai, Ching-Chun Lin, Wen-Yuan Lin, Chiu-Shong Liu, Tsung-Po Chen. Clinical and Metabolic Characteristics of Hyperuricemia with Risk of Liver Fibrosis: A Cross-Sectional Study. Metabolites 2022; 12(10): 893 doi: 10.3390/metabo12100893
|
4 |
Akira Sasaki, Akira Umemura, Kazuyuki Ishida, Naoto Takahashi, Haruka Nikai, Hiroyuki Nitta, Yasuhiro Takikawa, Keisuke Kakisaka, Tamami Abe, Masao Nishiya, Tamotsu Sugai. The Concept of Indeterminable NASH Inducted by Preoperative Diet and Metabolic Surgery: Analyses of Histopathological and Clinical Features. Biomedicines 2022; 10(2): 453 doi: 10.3390/biomedicines10020453
|
5 |
Pei Chia Eng, Roberta Forlano, Tricia Tan, Pinelopi Manousou, Waljit S. Dhillo, Chioma Izzi-Engbeaya. Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts. JHEP Reports 2023; 5(10): 100835 doi: 10.1016/j.jhepr.2023.100835
|
6 |
Michelle J Allen, Rachael Doran, David Brain, Elizabeth E Powell, James O’Beirne, Patricia C Valery, Adrian Barnett, Ruvini Hettiarachchi, Ingrid J Hickman, Sanjeewa Kularatna. A discrete choice experiment to elicit preferences for a liver screening programme in Queensland, Australia: a mixed methods study to select attributes and levels. BMC Health Services Research 2023; 23(1) doi: 10.1186/s12913-023-09934-2
|
7 |
Mohamed El-Kassas, Heba A. Othman, Mohamed Elbadry, Khalid Alswat, Yusuf Yilmaz. Risk Stratification of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: Steatohepatitis, Fibrosis, and Hepatocellular Carcinoma. Journal of Clinical and Experimental Hepatology 2024; : 102415 doi: 10.1016/j.jceh.2024.102415
|
8 |
Neues zur Fettleber: Nomenklatur, Screening-Empfehlungen, Therapiebemühungen und andere klinisch relevante Aspekte. Zeitschrift für Gastroenterologie 2023; 61(10): 1419 doi: 10.1055/a-2149-7976
|
9 |
Tanmoy Mondal, Coleman I. Smith, Christopher A. Loffredo, Ruth Quartey, Gemeyel Moses, Charles D. Howell, Brent Korba, Bernard Kwabi-Addo, Gail Nunlee-Bland, Leanna R. Rucker, Jheannelle Johnson, Somiranjan Ghosh. Transcriptomics of MASLD Pathobiology in African American Patients in the Washington DC Area †. International Journal of Molecular Sciences 2023; 24(23): 16654 doi: 10.3390/ijms242316654
|
10 |
Michael H. Storandt, Sri Harsha Tella, Mikolaj A. Wieczorek, David Hodge, Julia K. Elrod, Philip S. Rosenberg, Zhaohui Jin, Amit Mahipal. Projected Incidence of Hepatobiliary Cancers and Trends Based on Age, Race, and Gender in the United States. Cancers 2024; 16(4): 684 doi: 10.3390/cancers16040684
|
11 |
Jhon Edison Prieto Ortíz, Carlos Bernardo Sánchez Luque, Rolando José Ortega Quiróz. Hígado graso (parte 2): enfoque clínico y tratamiento. Revista colombiana de Gastroenterología 2023; 38(1): 46 doi: 10.22516/25007440.979
|
12 |
Giovanna McGinty, Robert Przemioslo. Effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease: Clinical implications. World Journal of Gastroenterology 2024; 30(27): 3264-3267 doi: 10.3748/wjg.v30.i27.3264
|
13 |
Adnan Khan, Heather M. Ross, Natalia Salinas Parra, Sarah L. Chen, Kashyap Chauhan, Makala Wang, Brian Yan, John Magagna, Jake Beiriger, Yash Shah, Taha Shahzad, Dina Halegoua-DeMarzio. Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD). Livers 2022; 2(4): 264 doi: 10.3390/livers2040022
|
14 |
Menooa Ebrahimi, Seyed Arsalan Seyedi, Seyed Ali Nabipoorashrafi, Soghra Rabizadeh, Mojdeh Sarzaeim, Amirhossein Yadegar, Fatemeh Mohammadi, Razman Arabzadeh Bahri, Peyman Pakravan, Paria Shafiekhani, Manouchehr Nakhjavani, Alireza Esteghamati. Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Lipids in Health and Disease 2023; 22(1) doi: 10.1186/s12944-023-01802-6
|
15 |
Barbara Janota, Elżbieta Szczepańska, Brygida Adamek, Ewa Janczewska. Hypothyroidism and non-alcoholic fatty liver disease: A coincidence or a causal relationship?. World Journal of Hepatology 2023; 15(5): 641-648 doi: 10.4254/wjh.v15.i5.641
|
16 |
Mohamed El-Kassas, Abeer Awad, Mohamed Elbadry, Juan Pablo Arab. Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. Seminars in Liver Disease 2024; 44(01): 054 doi: 10.1055/a-2253-9181
|
17 |
Stefano Mazza, Sara Soro, Maria Chiara Verga, Biagio Elvo, Francesca Ferretti, Fabrizio Cereatti, Andrea Drago, Roberto Grassia. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. World Journal of Hepatology 2021; 13(12): 1828-1849 doi: 10.4254/wjh.v13.i12.1828
|